Kura Oncology, Inc. (KURA) 8-K Current Report — March 5, 2026
Filed: March 5, 2026
Health Care
Pharmaceutical PreparationsKura Oncology, Inc. (KURA) 8-K current report filed with SEC EDGAR on March 5, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
Kura Oncology, Inc. 8-K Mar 5, 2026 Event Analysis
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced March 5, 2026 — full figures in Exhibit 99.1
- • KURA is a clinical-stage oncology company; results likely reflect R&D spend, cash runway, and pipeline progress rather than product revenue
Get deeper insights on Kura Oncology, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.